Cetuximab in der first-line-therapie des kolonkarzinoms: Neue studie zeigt erstmals ein medianes überleben von 30 monaten

Research output: Contribution to journalComment/DebateContributedpeer-review

Contributors

Translated title of the contribution
Cetuximab in the first-line therapy of colon cancer
A new study shows for the first time a median survival of 30 months

Details

Original languageGerman
Pages (from-to)XII
Journal Klinikarzt : Medizin im Krankenhaus
Volume34
Issue number10
Publication statusPublished - 2005
Peer-reviewedYes

External IDs

ORCID /0000-0002-9321-9911/work/142251997

Keywords

ASJC Scopus subject areas